Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer
Quick Facts
- Publication title: Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer
- Journal: Pharmacol Res
- Year: 2023
- DOI: 10.1016/j.phrs.2023.106921
- PMID/PMCID: 37709184
Research overview
Neoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC). Our results demonstrate that the exLR-based signature could accurately predict responses to neoadjuvant immunotherapy and prognosis in NSCLC patients.
Key findings
Neoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC).
However, limited by the lack of clinically feasible markers, it is still difficult to select NSCLC patients who respond well and to predict patients' clinical outcomes before the treatment.
Before the treatment, we isolated plasma extracellular vesicles (EVs) from three cohorts (discovery, training and validation) of 78 NSCLC patients treated with neoadjuvant immunotherapy.
To identify differentially-expressed EV long RNAs (exLRs), we employed RNA-seq in the discovery cohort.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, lncRNA/mRNA sequencing, qPCR validation; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV lncRNA/mRNA Sequencing, qPCR Validation, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer Pharmacol Res. 2023. DOI: 10.1016/j.phrs.2023.106921. PMID/PMCID: 37709184.